Alumis (ALMS) stock has been in focus after the company reported late breaking Phase 3 data for its oral TYK2 inhibitor envudeucitinib in moderate to severe plaque psoriasis, alongside weaker Q1 2026 revenue.
See our latest analysis for Alumis.
Despite the latest 1-day share price return falling 7.15% and shorter-term pressure, including a 30-day share price return down 8.48%, Alumis still shows very strong momentum over a longer horizon, with a 1-year total shareholder return of about 2.8x.
If this kind of clinical news has your attention, it can be a useful moment to look at other potential biotech opportunities through our focused healthcare AI stock screener, starting with 28 healthcare AI stocks.
With the stock pulling back in the short term but delivering about a 2.8x total return over the past year, the key question now is whether Alumis is undervalued after recent data or if the market is already pricing in future growth.
Preferred Price to Book Multiple of 5.1x: Is it justified?
Alumis currently trades on a P/B ratio of 5.1x, which places a clear premium on the $22.87 share price compared with many peers in the sector.
P/B compares the company's market value to its book value, so for a clinical stage biopharmaceutical business that is still loss making, a higher ratio typically reflects investor focus on future pipeline potential rather than current profitability.
In this case, the market appears willing to pay more than 5 times the accounting value of Alumis's net assets, even though the company is unprofitable, is forecast to remain loss making over the next 3 years, has a negative return on equity and has seen shareholders substantially diluted over the past year.
That premium also stands out against both the US pharmaceuticals industry average P/B of 2.2x and the peer group average of 4.5x, which suggests investors are assigning Alumis a higher valuation multiple than many comparable stocks.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 5.1x (OVERVALUED)
However, there are clear risks, including ongoing losses, with net income at a loss of US$237.415 million and a market value of about US$2.9b resting on early stage assets.
Find out about the key risks to this Alumis narrative.
Next Steps
If this mix of strong past returns and clear risk factors leaves you undecided, it is worth considering a closer look at the data yourself to see whether the trade off suits your own risk tolerance, starting with the 1 key reward and 2 important warning signs.
Looking for more investment ideas?
If Alumis is already on your radar, it makes sense to keep building your watchlist with other stocks that fit clear, well defined criteria using the Simply Wall St screener.
- Target potential mispricings by scanning for companies that combine quality fundamentals with attractive valuations through the 51 high quality undervalued stocks.
- Strengthen your income focus by reviewing stocks that offer robust yields and resilient cash flows using the 14 dividend fortresses.
- Prioritize resilience by filtering for companies with lower risk scores and steadier profiles via the 66 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com